Patents by Inventor Michiel Luc Maria Van Gool

Michiel Luc Maria Van Gool has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NEW COMPOUND
    Publication number: 20240043450
    Abstract: The invention relates to novel compounds for use as inhibitors of NLRP3 inflammasome production, wherein such compounds are as defined by compounds of formula (I) and wherein the integers R1, R2 and R3 are defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of a disease or disorder that is associated with NLRP3 inflammasome activity.
    Type: Application
    Filed: September 23, 2021
    Publication date: February 8, 2024
    Inventors: Daniel OEHLRICH, Nina VAN OPDENBOSCH, Michiel Luc Maria VAN GOOL, Dries VAN ROMPAEY, Gary John TRESADERN, Josep LLAVERIA CROS, Mohamed LAMKANFI
  • NEW COMPOUND
    Publication number: 20230391756
    Abstract: The invention relates to novel compounds for use as inhibitors of NL-RP3 inflammasone production, wherein such compounds are as defined by compounds of formula (I) and wherein the integers R1, R2 and R3 are defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of a disease or disorder that is associated with NLRP3 inflammasome activity.
    Type: Application
    Filed: September 23, 2021
    Publication date: December 7, 2023
    Inventors: Daniel OEHLRICH, Michiel Luc Maria VAN GOOL, Joseph Elisabeth LEENAERTS, Michael Eric MURATORE, Gary John TRESADERN, Mohamed LAMKANFI, Nina VAN OPDENBOSCH, Robert Than HENDRICKS
  • COMPOUNDS
    Publication number: 20230202989
    Abstract: The invention relates to novel compounds for use as inhibitors of NLRP3 inflammasone production, wherein such compounds are as defined by compounds of formula (I) and wherein the integers R1, R2 and R3 are defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of a disease or disorder that is associated with NLRP3 inflammasome activity.
    Type: Application
    Filed: May 27, 2021
    Publication date: June 29, 2023
    Inventors: Michael Eric MURATORE, Nina VAN OPDENBOSCH, Joseph Elisabeth LEENAERTS, Mohamed LAMKANFI, Gary John TRESADERN, Daniel OEHLRICH, Michiel Luc Maria VAN GOOL, Laura PEREZ BENITO
  • TRICYCLIC COMPOUNDS AS INHIBITORS OF NLRP3
    Publication number: 20230203064
    Abstract: The invention relates to novel compounds for use as inhibitors of NLRP3 inflammasone production, wherein such compounds are as defined by compounds of formula (I) and wherein the integers R1, R2 and R3 are defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of a disease or disorder that is associated with NLRP3 inflammasome activity.
    Type: Application
    Filed: April 23, 2021
    Publication date: June 29, 2023
    Inventors: Daniel OEHLRICH, Nina VAN OPDENBOSCH, Mohamed LAMKANFI, Alejandro DIÉGUEZ-VÁZQUEZ, Michiel Luc Maria VAN GOOL, Santiago CAÑELLAS ROMAN
  • PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME
    Publication number: 20230203044
    Abstract: The invention relates to novel compounds for use as in-hibitors of NLRP3 inflammasone production, wherein such compounds are as defined by compounds of formula (I) and wherein the integers R1, R2 and R3 are defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of a disease or disorder that is associated with NLRP3 inflammasome activity.
    Type: Application
    Filed: April 15, 2021
    Publication date: June 29, 2023
    Inventors: Daniel OEHLRICH, Michiel Luc Maria VAN GOOL, Nina VAN OPDENBOSCH, Mohamed LAMKANFI, Josep LLAVERIA CROS, Carlos Manuel MARTINEZ VITURRO, Dries VAN ROMPAEY
  • NEW TRIAZINOINDOLE COMPOUNDS
    Publication number: 20230183249
    Abstract: The invention relates to novel compounds for use as inhibitors of NLRP3 inflammasome production, wherein such compounds are as defined by compounds of formula (I) and wherein the integers R1, R2, R3a and R3b are defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of a disease or disorder that is associated with NLRP3 inflammasome activity.
    Type: Application
    Filed: April 29, 2021
    Publication date: June 15, 2023
    Inventors: Daniel OEHLRICH, Michiel Luc Maria VAN GOOL, Juan Antonio VEGA RAMIRO, Mohamed LAMKANFI, Nina VAN OPDENBOSCH
  • PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY
    Publication number: 20230183248
    Abstract: The invention relates to novel compounds for use as inhibitors of NLRP3 inflammasone production, wherein such compounds are as defined by compounds of formula (I), Formula (I) and wherein the integers R1, R2 and R3 are defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of a disease or disorder that is associated with NLRP3 inflammasome activity.
    Type: Application
    Filed: April 15, 2021
    Publication date: June 15, 2023
    Inventors: Daniel OEHLRICH, Michiel Luc Maria VAN GOOL, Nina VAN OPDENBOSCH, Mohamed LAMKANFI, Joseph Elisabeth LEENAERTS, Carlos Manuel MARTINEZ VITURRO, Michael Eric MURATORE
  • Radiolabelled mGluR2/3 PET ligands
    Patent number: 11045562
    Abstract: The present invention relates to novel, radiolabeled mGluR2/3 ligands, selective versus other mGlu receptors which are useful for imaging and quantifying the metabotropic glutamate receptor mGlu2 and 3 in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the use of such compounds and compositions for imaging a tissue, cells or a mammal, in vitro or in vivo and to precursors of said compounds.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: June 29, 2021
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: José Ignacio Andrés-Gil, Michiel Luc Maria Van Gool, Guy Maurits R Bormans, Joost Verbeek
  • RADIOLABELLED mGluR2 PET LIGANDS
    Publication number: 20210177995
    Abstract: The present invention relates to novel, selective, radiolabelled mGluR2 ligands which are useful for imaging and quantifying the metabotropic glutamate receptor mGluR2 in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the use of such compounds and compositions for imaging a tissue, cells or a mammal, in vitro or in vivo and to precursors of said compounds.
    Type: Application
    Filed: February 26, 2021
    Publication date: June 17, 2021
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Michiel Luc, Maria VAN GOOL, José Ignacio ANDRÉS-GIL, Manuel Jesús ALCÁZAR-VACA, Guy Maurits R. BORMANS, Sofie Jeanne Leopoldine CELEN, Joost VERBEEK
  • Radiolabelled mGluR2/3 pet ligands
    Patent number: 11033641
    Abstract: The present invention relates to novel, radiolabelled mGluR2/3 ligands, selective 5 versus other mGlu receptors, which are useful for imaging and quantifying the metabotropic glutamate receptors mGlu2 and 3 in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the use of such compounds and compositions for imaging a tissue, cells or a mammal, in vitro or 10 in vivo and to precursors of said compounds.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: June 15, 2021
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: José Ignacio Andrés-Gil, Michiel Luc Maria Van Gool, Guy Maurits R Bormans, Joost Verbeek
  • Radiolabelled mGluR2 PET ligands
    Patent number: 10967078
    Abstract: The present invention relates to novel, selective, radiolabelled mGluR2 ligands which are useful for imaging and quantifying the metabotropic glutamate receptor mGluR2 in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the use of such compounds and compositions for imaging a tissue, cells or a mammal, in vitro or in vivo and to precursors of said compounds.
    Type: Grant
    Filed: December 2, 2015
    Date of Patent: April 6, 2021
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Michiel Luc Maria Van Gool, José Ignacio Andrés-Gil, Manuel Jesús Alcázar-Vaca, Guy Maurits R. Bormans, Sofie Jeanne Leopoldine Celen, Joost Verbeek
  • RADIOLABELLED mGluR2/3 PET LIGANDS
    Publication number: 20200306389
    Abstract: The present invention relates to novel, radiolabelled mGluR2/3 ligands, selective 5 versus other mGlu receptors, which are useful for imaging and quantifying the metabotropic glutamate receptors mGlu2 and 3 in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the use of such compounds and compositions for imaging a tissue, cells or a mammal, in vitro or 10 in vivo and to precursors of said compounds.
    Type: Application
    Filed: December 16, 2016
    Publication date: October 1, 2020
    Inventors: José Ignacio Andrés-Gil, Michiel Luc Maria Van Gool, Guy Maurits R Bormans, Joost Verbeek
  • 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
    Publication number: 20200261450
    Abstract: The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 (“mGluR2”). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved.
    Type: Application
    Filed: May 4, 2020
    Publication date: August 20, 2020
    Inventors: Susana Conde-Ceide, Michiel Luc, Maria Van Gool, María Luz Martín-Martín
  • 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one compounds and their use as negative allosteric modulators of mGluR2 receptors
    Patent number: 10668065
    Abstract: The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives of Formula I as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 (“mGluR2”). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: June 2, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Susana Conde-Ceide, Michiel Luc Maria Van Gool, María Luz Martín-Martín
  • SUBSTITUTED 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZINES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
    Publication number: 20200121677
    Abstract: The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 (“mGluR2”). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved.
    Type: Application
    Filed: November 7, 2019
    Publication date: April 23, 2020
    Applicant: Janssen Pharmaceutica NV
    Inventors: Sergio-Alvar Alonso-de Diego, Michiel Luc, Maria Van Gool, Óscar Delgado-González, José Ignacio Andrés-Gil, Andrés Avelino Trabanco-Suárez
  • Substituted 6,7-dihydropyrazolo[1,5-a]pyrazines as negative allosteric modulators of mGluR2 receptors
    Patent number: 10584129
    Abstract: The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 (“mGluR2”). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: March 10, 2020
    Assignee: Janssen Pharmaceuticals NV
    Inventors: Sergio-Alvar Alonso-de Diego, José Maria Cid-Núñez, Óscar Delgado-González, Annelies Marie Antonius Decorte, Michiel Luc Maria Van Gool, Gregor James MacDonald, Antonius Adrianus Hendrikus Petrus Megens, Andrés Avelino Trabanco-Suárez, Aránzazu García-Molina, José Ignacio Andrés-Gil
  • 6,7-dihydropyrazolo[1,5-?]pyrazin-4(5H)-one compounds and their use as negative allosteric modulators of mGluR2 receptors
    Patent number: 10519162
    Abstract: The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives of Formula (I) as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 (“mGluR2”). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: December 31, 2019
    Assignee: Janssen Pharmaceutica NV
    Inventors: Sergio-Alvar Alonso-de Diego, Michiel Luc Maria Van Gool, Maria Luz Martin-Martin, Susana Conde-Ceide, José Ignacio Andrés-Gil, Óscar Delgado-González, Gary John Tresadern, Andrés Avelino Trabanco-Suárez
  • Substituted 6,7-dihydropyrazolo[1,5-a]pyrazines as negative allosteric modulators of mGluR2 receptors
    Patent number: 10512646
    Abstract: The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives of Formula (I) as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 (“mGluR2”). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: December 24, 2019
    Assignee: Janssen Pharmaceutica NV
    Inventors: Sergio-Alvar Alonso-de Diego, Michiel Luc Maria Van Gool, Óscar Delgado-González, José Ignacio Andrés-Gil, Andrés Avelino Trabanco-Suárez
  • 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
    Publication number: 20190160061
    Abstract: The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 (“mGluR2”). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved.
    Type: Application
    Filed: January 31, 2019
    Publication date: May 30, 2019
    Inventors: Susana Conde-Ceide, Michiel Luc, Maria Van Gool, María Luz Martín-Martín
  • 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one compounds and their use as negative allosteric modulators of mGluR2 receptors
    Patent number: 10220032
    Abstract: The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor sub-type 2 (“mGluR2”) of Formula I: The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such com-pounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved.
    Type: Grant
    Filed: July 30, 2015
    Date of Patent: March 5, 2019
    Assignee: Janssen Pharmaceutica NV
    Inventors: Susana Conde-Ceide, Michiel Luc Maria Van Gool, María Luz Martín-Martín